Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sts Clear all
Active, not recruiting Phase 3 Interventional

Preoperative vs Postoperative IMRT for Extremity/Truncal STS

NCT02565498
View directory record Official record
Conditions
Adult Soft Tissue Sarcoma
Interventions
Preoperative intensity modulated radiation therapy, Postoperative intensity modulated radiation therapy
Radiation
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jun 26, 2026, 9:23 AM EDT
Completed No phase listed Observational

National Registry for Ichthyosis and Related Disorders

NCT00074685
View directory record Official record
Conditions
Darier Disease, Hailey-Hailey Disease, Hyperkeratosis, Epidermolytic, Ichthyosis, Ichthyosis, Lamellar, Ichthyosis, X-Linked, Keratoderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jun 26, 2026, 9:23 AM EDT
Not yet recruiting Early Phase 1 Interventional

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

NCT07038278
View directory record Official record
Conditions
Soft Tissue Sarcoma (STS)
Interventions
5-ALA
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Results available

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

NCT03217266
View directory record Official record
Conditions
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Interventions
Navtemadlin, Radiation Therapy, Surgical Procedure
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
53
States / cities
Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jun 26, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Doxorubicin and Avastin® in Sarcoma.

NCT00755261
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma
Interventions
Avastin, Doxorubicin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Jun 26, 2026, 9:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

NCT00983398
View directory record Official record
Conditions
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma, Medulloepithelioma, Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Germ Cell Tumor, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
Interventions
Carboplatin, Mannitol, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis

NCT01572844
View directory record Official record
Conditions
Calcinosis
Interventions
Fractionated Carbon Dioxide (FCO2) Laser, Sodium thiosulfate
Device · Drug
Lead sponsor
Alison Ehrlich
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jun 26, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma

NCT06905132
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

NCT00571298
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Extrapleural pneumonectomy (EPP), Cisplatin, gemcitabine, amifostine, sodium thiosulfate, Pleurectomy/Decortication
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

NCT02549937
View directory record Official record
Conditions
Tumors
Interventions
surufatinib
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jun 26, 2026, 9:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT05688280
View directory record Official record
Conditions
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions
1.0% IP-001 for Injection
Drug
Lead sponsor
Immunophotonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jun 26, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

NCT05432193
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
Interventions
[Ga-68]-PNT6555, [Lu-177]-PNT6555
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 26, 2026, 9:23 AM EDT
Withdrawn Phase 3 Interventional

Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy

NCT02527213
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Sodium thiosulfate, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Huntsville, Alabama • Fort Wayne, Indiana • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jun 26, 2026, 9:23 AM EDT
Suspended Early Phase 1 Interventional

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

NCT05756660
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
Sodium Thiosulfate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 39 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 26, 2026, 9:23 AM EDT
Recruiting No phase listed Observational

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

NCT01737528
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
The Society of Thoracic Surgeons
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

NCT00276302
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

NCT01347034
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
External Beam Radiation Therapy (RT), Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jun 26, 2026, 9:23 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

NCT00075387
View directory record Official record
Conditions
Malignant Glioma
Interventions
Carboplatin, Cyclophosphamide, Etoposide Phosphate, Quality-of-Life Assessment, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
3
States / cities
Minneapolis, Minnesota • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Jun 26, 2026, 9:23 AM EDT
Not listed Phase 1 Interventional

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

NCT04032964
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
L19TNF, DOXORUBICIN
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 26, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 26, 2026, 9:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

NCT07407582
View directory record Official record
Conditions
Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer
Interventions
Pedmark® STS
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

NCT00640614
View directory record Official record
Conditions
Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Jun 26, 2026, 9:23 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

NCT06413095
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jun 26, 2026, 9:23 AM EDT
Active, not recruiting Phase 1 Interventional

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

NCT05813327
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions
ADI PEG20, Ifosfamide, Radiotherapy, Mesna
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 26, 2026, 9:23 AM EDT